07.08.2012 • Product

Clariant Presents Pharma Processing Solutions

Clariant's promise to create added value by appreciating the needs of its pharmaceutical sector customers will take center stage at the CPhI 2012. Presented for the first time under the company's new branding, the specialty chemicals expert's trusted high purity processing solutions can help meet the efficiency and performance requirements of specific pharmaceutical formulations. Clariant is a firm believer in working closely with customers in order to maximize the benefits of its portfolio of building blocks, enhancers, and ingredients for the processing of sensitive applications.

A highlight for CPhI 2012 visitors will be Clariant's portfolio of Pharmaceutical PEGs/ Macrogols, a product range under the trade name Polyglykol, used as API in laxatives and as excipients for tablets, suppository masses, organ preservation, protein purification and drug delivery systems. Clariant offers a complete range of different molecular weight, high purity PEGs supported by CEP certification and DMF.

"Appreciation is the key to delivering the innovative and competitive processing solutions required by the pharmaceutical sector. This philosophy of listening to our customers is at the heart of Clariant and we are excited to have the opportunity to present this to the pharmaceutical community within the fresh look and feel of our new company branding at the forthcoming CPhI," comments Boris Segalowitch, Business Line Head Personal Care EMEA, Clariant.

 

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read